- ANTX Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing Data
AN2 Therapeutics (ANTX) 8-K13 Sep 23Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024Financial data
Company Profile